Improved Tumor Response in Patients on Metformin Undergoing Yttrium-90 Radioembolization Segmentectomy for Hepatocellular Carcinoma

[1]  Wei Zhang,et al.  Metformin: current clinical applications in nondiabetic patients with cancer , 2020, Aging.

[2]  H. Cotrim,et al.  Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review. , 2019, Annals of hepatology.

[3]  R. Gandhi,et al.  Patient Selection and Clinical Outcomes of Y90 in Hepatocellular Carcinoma. , 2019, Techniques in vascular and interventional radiology.

[4]  Y. Abe,et al.  Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification , 2018, Hepatology.

[5]  C. Tseng.  Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[6]  R. Salem,et al.  Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma , 2018, CardioVascular and Interventional Radiology.

[7]  B. Guo,et al.  Mechanisms of resistance to chemotherapy and radiotherapy in hepatocellular carcinoma , 2018, Translational Cancer Research.

[8]  P. Lucatelli,et al.  Trans-arterial radio-embolization: a new chance for patients with hepatocellular cancer to access liver transplantation, a world review. , 2017, Translational gastroenterology and hepatology.

[9]  M. Leech,et al.  Metformin and improved treatment outcomes in radiation therapy - A review. , 2017, Cancer treatment reviews.

[10]  A. Rademaker,et al.  Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. , 2016, Gastroenterology.

[11]  G. Lauwers,et al.  Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis , 2016, Cancer.

[12]  H. Choi,et al.  Association of Metformin Use With Cancer-Specific Mortality in Hepatocellular Carcinoma After Curative Resection , 2016, Medicine.

[13]  M. Koritzinsky.  Metformin: A Novel Biological Modifier of Tumor Response to Radiation Therapy. , 2015, International journal of radiation oncology, biology, physics.

[14]  H. Jang,et al.  Survival Advantage Associated with Metformin Usage in Hepatocellular Carcinoma Patients Receiving Radiotherapy: A Propensity Score Matching Analysis. , 2015, Anticancer research.

[15]  D. Schuster,et al.  (90)Y Radioembolization: Multimodality Imaging Pattern Approach with Angiographic Correlation for Optimized Target Therapy Delivery. , 2015, Radiographics : a review publication of the Radiological Society of North America, Inc.

[16]  M. Peppelenbosch,et al.  Anti-Tumor Effects of Metformin in Animal Models of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis , 2015, PloS one.

[17]  P. Pockros,et al.  Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma. , 2015, Journal of gastrointestinal oncology.

[18]  M. Abecassis,et al.  Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: Multicenter radiology‐pathology correlation and survival of radiation segmentectomy , 2014, Hepatology.

[19]  Lisa S. Smith,et al.  Safety and Efficacy of Metformin in Patients With Type 2 Diabetes Mellitus and Chronic Hepatitis C , 2013, The Annals of pharmacotherapy.

[20]  L. Tang,et al.  Prognostic Significance of AMPK Activation and Therapeutic Effects of Metformin in Hepatocellular Carcinoma , 2013, Clinical Cancer Research.

[21]  Hao Li,et al.  Association of metformin use with cancer incidence and mortality: a meta-analysis. , 2013, Cancer epidemiology.

[22]  S. Yao,et al.  Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis , 2013, Scandinavian journal of gastroenterology.

[23]  E. Vicaut,et al.  Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. , 2011, The Journal of clinical endocrinology and metabolism.

[24]  K. Delman,et al.  Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. , 2010, Journal of vascular and interventional radiology : JVIR.

[25]  R. Golfieri,et al.  Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation , 2016, World Journal of Surgery.

[26]  A. Benson,et al.  Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. , 2011, International journal of radiation oncology, biology, physics.